ARK 每周股评 – 9/17/2022

我们每周都会与投资者分享我们策略中一周内一天内升值或下跌超过15%的股票的周评。我们希望您觉得这篇评论有用。

We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Recursion Pharmaceuticals (RXRX)
-17%Shares of Recursion Pharmaceuticals traded down ~17% Friday, participating in a broad market slump catalyzed by macroeconomic uncertainty. On Tuesday, the company announced its launch of clinical trials for REC-4481 and REC-396, two drugs aiming to treat familial adenomatous polyposis and Clostridium difficile infection. Recursion is a young platform-based therapeutics company industrializing drug discovery. Its key differentiator, Recursion OS, integrates exponential growth technologies spanning wet and dry-lab biology with the goal of optimizing preclinical success.

注:周五,Recursion Pharmaceuticals的股票下跌了约17%,参与了由宏观经济不确定性催化的广泛的市场低迷。周二,该公司宣布启动REC-4481和REC-396的临床试验,这两种药物旨在治疗家族性腺瘤性息肉病和艰难梭菌感染。Recursion是一家年轻的基于平台的治疗公司,将药物发现产业化。其关键的差异化产品Recursion OS整合了跨越湿法和干法实验室生物学的指数增长技术,目的是优化临床前的成功。

主题测试文章,只做测试使用。发布者:star,转转请注明出处:https://wallstreetgm.com/ark-%e6%af%8f%e5%91%a8%e8%82%a1%e8%af%84-9-17-2022/

(0)
上一篇 2022年9月18日 下午4:29
下一篇 2022年9月21日 下午2:07

相关推荐

发表回复

您的电子邮箱地址不会被公开。 必填项已用*标注